Cargando…

Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor

Of the patients infected with coronavirus disease 2019 (COVID-19), approximately 14–53% developed liver injury resulting in poor outcomes. Drug-induced liver injury (DILI) is the primary cause of liver injury in COVID-19 patients. In this study, we elucidated liver injury mechanism induced by drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jingjing, Zhang, Zhaokang, Hao, Chenxia, Qiu, Yuzhen, Tan, Ruoming, Liu, Jialin, Wang, Xiaoli, Yang, Wanhua, Qu, Hongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377275/
https://www.ncbi.nlm.nih.gov/pubmed/35979235
http://dx.doi.org/10.3389/fphar.2022.804189
_version_ 1784768307385073664
author Huang, Jingjing
Zhang, Zhaokang
Hao, Chenxia
Qiu, Yuzhen
Tan, Ruoming
Liu, Jialin
Wang, Xiaoli
Yang, Wanhua
Qu, Hongping
author_facet Huang, Jingjing
Zhang, Zhaokang
Hao, Chenxia
Qiu, Yuzhen
Tan, Ruoming
Liu, Jialin
Wang, Xiaoli
Yang, Wanhua
Qu, Hongping
author_sort Huang, Jingjing
collection PubMed
description Of the patients infected with coronavirus disease 2019 (COVID-19), approximately 14–53% developed liver injury resulting in poor outcomes. Drug-induced liver injury (DILI) is the primary cause of liver injury in COVID-19 patients. In this study, we elucidated liver injury mechanism induced by drugs of pharmacologic treatments against SARS-CoV-2 (DPTS) using bioinformatics and systems biology. Totally, 1209 genes directly related to 216 DPTS (DPTSGs) were genes encoding pharmacokinetics and therapeutic targets of DPTS and enriched in the pathways related to drug metabolism of CYP450s, pregnane X receptor (PXR), and COVID-19 adverse outcome. A network, constructed by 110 candidate targets which were the shared part of DPTSGs and 445 DILI targets, identified 49 key targets and four Molecular Complex Detection clusters. Enrichment results revealed that the 4 clusters were related to inflammatory responses, CYP450s regulated by PXR, NRF2-regualted oxidative stress, and HLA-related adaptive immunity respectively. In cluster 1, IL6, IL1B, TNF, and CCL2 of the top ten key targets were enriched in COVID-19 adverse outcomes pathway, indicating the exacerbation of COVID-19 inflammation on DILI. PXR-CYP3A4 expression of cluster 2 caused DILI through inflammation-drug interaction and drug-drug interactions among pharmaco-immunomodulatory agents, including tocilizumab, glucocorticoids (dexamethasone, methylprednisolone, and hydrocortisone), and ritonavir. NRF2 of cluster 3 and HLA targets of cluster four promoted DILI, being related to ritonavir/glucocorticoids and clavulanate/vancomycin. This study showed the pivotal role of PXR associated with inflammation-drug and drug-drug interactions on DILI and highlighted the cautious clinical decision-making for pharmacotherapy to avoid DILI in the treatment of COVID-19 patients.
format Online
Article
Text
id pubmed-9377275
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93772752022-08-16 Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor Huang, Jingjing Zhang, Zhaokang Hao, Chenxia Qiu, Yuzhen Tan, Ruoming Liu, Jialin Wang, Xiaoli Yang, Wanhua Qu, Hongping Front Pharmacol Pharmacology Of the patients infected with coronavirus disease 2019 (COVID-19), approximately 14–53% developed liver injury resulting in poor outcomes. Drug-induced liver injury (DILI) is the primary cause of liver injury in COVID-19 patients. In this study, we elucidated liver injury mechanism induced by drugs of pharmacologic treatments against SARS-CoV-2 (DPTS) using bioinformatics and systems biology. Totally, 1209 genes directly related to 216 DPTS (DPTSGs) were genes encoding pharmacokinetics and therapeutic targets of DPTS and enriched in the pathways related to drug metabolism of CYP450s, pregnane X receptor (PXR), and COVID-19 adverse outcome. A network, constructed by 110 candidate targets which were the shared part of DPTSGs and 445 DILI targets, identified 49 key targets and four Molecular Complex Detection clusters. Enrichment results revealed that the 4 clusters were related to inflammatory responses, CYP450s regulated by PXR, NRF2-regualted oxidative stress, and HLA-related adaptive immunity respectively. In cluster 1, IL6, IL1B, TNF, and CCL2 of the top ten key targets were enriched in COVID-19 adverse outcomes pathway, indicating the exacerbation of COVID-19 inflammation on DILI. PXR-CYP3A4 expression of cluster 2 caused DILI through inflammation-drug interaction and drug-drug interactions among pharmaco-immunomodulatory agents, including tocilizumab, glucocorticoids (dexamethasone, methylprednisolone, and hydrocortisone), and ritonavir. NRF2 of cluster 3 and HLA targets of cluster four promoted DILI, being related to ritonavir/glucocorticoids and clavulanate/vancomycin. This study showed the pivotal role of PXR associated with inflammation-drug and drug-drug interactions on DILI and highlighted the cautious clinical decision-making for pharmacotherapy to avoid DILI in the treatment of COVID-19 patients. Frontiers Media S.A. 2022-08-01 /pmc/articles/PMC9377275/ /pubmed/35979235 http://dx.doi.org/10.3389/fphar.2022.804189 Text en Copyright © 2022 Huang, Zhang, Hao, Qiu, Tan, Liu, Wang, Yang and Qu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Huang, Jingjing
Zhang, Zhaokang
Hao, Chenxia
Qiu, Yuzhen
Tan, Ruoming
Liu, Jialin
Wang, Xiaoli
Yang, Wanhua
Qu, Hongping
Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor
title Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor
title_full Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor
title_fullStr Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor
title_full_unstemmed Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor
title_short Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor
title_sort identifying drug-induced liver injury associated with inflammation-drug and drug-drug interactions in pharmacologic treatments for covid-19 by bioinformatics and system biology analyses: the role of pregnane x receptor
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377275/
https://www.ncbi.nlm.nih.gov/pubmed/35979235
http://dx.doi.org/10.3389/fphar.2022.804189
work_keys_str_mv AT huangjingjing identifyingdruginducedliverinjuryassociatedwithinflammationdruganddrugdruginteractionsinpharmacologictreatmentsforcovid19bybioinformaticsandsystembiologyanalysestheroleofpregnanexreceptor
AT zhangzhaokang identifyingdruginducedliverinjuryassociatedwithinflammationdruganddrugdruginteractionsinpharmacologictreatmentsforcovid19bybioinformaticsandsystembiologyanalysestheroleofpregnanexreceptor
AT haochenxia identifyingdruginducedliverinjuryassociatedwithinflammationdruganddrugdruginteractionsinpharmacologictreatmentsforcovid19bybioinformaticsandsystembiologyanalysestheroleofpregnanexreceptor
AT qiuyuzhen identifyingdruginducedliverinjuryassociatedwithinflammationdruganddrugdruginteractionsinpharmacologictreatmentsforcovid19bybioinformaticsandsystembiologyanalysestheroleofpregnanexreceptor
AT tanruoming identifyingdruginducedliverinjuryassociatedwithinflammationdruganddrugdruginteractionsinpharmacologictreatmentsforcovid19bybioinformaticsandsystembiologyanalysestheroleofpregnanexreceptor
AT liujialin identifyingdruginducedliverinjuryassociatedwithinflammationdruganddrugdruginteractionsinpharmacologictreatmentsforcovid19bybioinformaticsandsystembiologyanalysestheroleofpregnanexreceptor
AT wangxiaoli identifyingdruginducedliverinjuryassociatedwithinflammationdruganddrugdruginteractionsinpharmacologictreatmentsforcovid19bybioinformaticsandsystembiologyanalysestheroleofpregnanexreceptor
AT yangwanhua identifyingdruginducedliverinjuryassociatedwithinflammationdruganddrugdruginteractionsinpharmacologictreatmentsforcovid19bybioinformaticsandsystembiologyanalysestheroleofpregnanexreceptor
AT quhongping identifyingdruginducedliverinjuryassociatedwithinflammationdruganddrugdruginteractionsinpharmacologictreatmentsforcovid19bybioinformaticsandsystembiologyanalysestheroleofpregnanexreceptor